×
Palvella Therapeutics Common Stock Net 2014-2024 | PVLA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Palvella Therapeutics common stock net from 2014 to 2024. Common stock net can be defined as the value of common equity ownership.
View More
Palvella Therapeutics Common Stock Net 2014-2024 | PVLA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Palvella Therapeutics common stock net from 2014 to 2024. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$153.4B
Gilead Sciences (GILD)
$121.1B
Bristol Myers Squibb (BMY)
$119.6B
Vertex Pharmaceuticals (VRTX)
$118.9B
CSL (CSLLY)
$83.5B
Regeneron Pharmaceuticals (REGN)
$74B
GSK (GSK)
$73.1B
Argenex SE (ARGX)
$39.8B
Alnylam Pharmaceuticals (ALNY)
$35B
BioNTech SE (BNTX)
$29.7B
BeiGene (ONC)
$22B
Illumina (ILMN)
$21.1B
Biogen (BIIB)
$21B
Moderna (MRNA)
$15.2B
Incyte (INCY)
$14.3B
Insmed (INSM)
$13.7B
Intra-Cellular Therapies (ITCI)
$13.5B
Genmab (GNMSF)
$13B
Genmab (GMAB)
$13B
BioMarin Pharmaceutical (BMRN)
$12.1B
Bio-Techne Corp (TECH)
$11.7B
Vaxcyte (PCVX)
$11B
Sarepta Therapeutics (SRPT)
$10.9B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
Exact Sciences (EXAS)
$10.4B
Bio-Rad Laboratories (BIO.B)
$10B
QIAGEN (QGEN)
$9.9B
Exelixis (EXEL)
$9.5B
Repligen (RGEN)
$9.3B
Roivant Sciences (ROIV)
$8.1B